Autolus Therapeutics (AUTL) EBITDA (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of EBITDA data on file, last reported at -$90.8 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA fell 62.43% year-over-year to -$90.8 million; the trailing twelve-month figure through Dec 2025 stood at -$263.7 million (down 19.41% YoY), and the FY2025 full-year result was -$263.7 million, down 19.41% from the prior year.
• EBITDA for Q4 2025 stood at -$90.8 million, down from -$84.9 million in the prior quarter.
• Across five years, EBITDA topped out at $40.5 million in Q3 2021 and bottomed at -$248.9 million in Q4 2021.
• The 5-year median for EBITDA is -$53.9 million (2024), against an average of -$50.4 million.
• The widest annual swing landed in 2022, when EBITDA surged 92.65%; it then sank 295.78% in 2023.
• A 5-year view of EBITDA shows it stood at -$248.9 million in 2021, then soared by 92.65% to -$18.3 million in 2022, then tumbled by 295.78% to -$72.4 million in 2023, then rose by 22.78% to -$55.9 million in 2024, then slumped by 62.43% to -$90.8 million in 2025.
• The last three EBITDA figures came in at -$90.8 million (Q4 2025), -$84.9 million (Q3 2025), and -$28.9 million (Q2 2025), per Business Quant data.

Peer Comparison